1. Home
  2. RYTM vs BMA Comparison

RYTM vs BMA Comparison

Compare RYTM & BMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$102.74

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Logo Banco Macro S.A.  ADR (representing Ten Class B)

BMA

Banco Macro S.A. ADR (representing Ten Class B)

HOLD

Current Price

$78.57

Market Cap

5.9B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
RYTM
BMA
Founded
2008
1966
Country
United States
Argentina
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Commercial Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
5.9B
IPO Year
2017
2006

Fundamental Metrics

Financial Performance
Metric
RYTM
BMA
Price
$102.74
$78.57
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
4
Target Price
$131.14
$99.33
AVG Volume (30 Days)
481.5K
333.6K
Earning Date
05-05-2026
05-27-2026
Dividend Yield
N/A
4.99%
EPS Growth
28.34
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$55.34
$16.25
Revenue Next Year
$86.06
N/A
P/E Ratio
N/A
$33.22
Revenue Growth
N/A
N/A
52 Week Low
$74.50
$38.30
52 Week High
$122.20
$106.15

Technical Indicators

Market Signals
Indicator
RYTM
BMA
Relative Strength Index (RSI) 41.15 44.79
Support Level $99.14 $71.46
Resistance Level $111.56 $94.64
Average True Range (ATR) 4.11 3.36
MACD -1.27 0.69
Stochastic Oscillator 6.89 78.32

Price Performance

Historical Comparison
RYTM
BMA

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

About BMA Banco Macro S.A. ADR (representing Ten Class B)

Banco Macro SA is a financial institution and it provides standard banking products and services designed to suit individual needs. It has two categories of customers, retail customers, which include individuals and entrepreneurs, and corporate customers, which include small, medium, and large companies and corporations. In addition, it provides services to four provincial governments. The company generates the majority of its revenue from Argentina.

Share on Social Networks: